Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer

OBJECTIVES: * Determine the antitumor activity of tipifarnib and trastuzumab (Herceptin) in patients with metastatic breast cancer. * Determine the safety and tolerability of this regimen in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive oral tipifarnib twice daily on days 1-21 and trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months. PROJECTED ACCRUAL: A total of 18-40 patients will be accrued for this study within 9-20 months.